Naranjo C A, Shear N H, Lanctôt K L
Clinical Pharmacology Program, Addiction Research Foundation, Toronto, Ontario, Canada.
J Clin Pharmacol. 1992 Oct;32(10):897-904. doi: 10.1002/j.1552-4604.1992.tb04635.x.
The clinician plays a key role in the detection and diagnosis of adverse drug reactions (ADRs). The diagnosis of ADRs, however, is a complex task. In the past, there were no systematically applied diagnostic criteria for ADRs, no formal methods of case analysis, no standardized epidemiologic approaches, and a limited knowledge of mechanisms. This resulted in the overdiagnosis of ADRs, which has negative consequences such as limiting treatment options. Recently, there have been various improvements in the diagnosis of ADRs, such as the development of standardized decision aids and of in vitro diagnostic tests. This article briefly reviews some of this knowledge, discusses the role of in vivo and in vitro rechallenge, and summarizes a probabilistic approach for collecting relevant information and diagnosing ADRs. The intention is to increase awareness of the different approaches for diagnosing ADRs as well as to stimulate researchers to continue to collect pharmacoepidemiologic information, study the pharmacologic, immunologic, and genetic factors involved in the pathogenesis of drug reactions, and develop and test new diagnostic instruments under various clinical conditions.
临床医生在药物不良反应(ADR)的检测和诊断中起着关键作用。然而,ADR的诊断是一项复杂的任务。过去,对于ADR没有系统应用的诊断标准,没有正式的病例分析方法,没有标准化的流行病学方法,并且对其机制的了解有限。这导致了ADR的过度诊断,产生了诸如限制治疗选择等负面后果。最近,ADR的诊断有了各种改进,例如标准化决策辅助工具和体外诊断测试的开发。本文简要回顾了其中一些知识,讨论了体内和体外激发试验的作用,并总结了一种收集相关信息和诊断ADR的概率方法。目的是提高对ADR不同诊断方法的认识,并激励研究人员继续收集药物流行病学信息,研究药物反应发病机制中涉及的药理、免疫和遗传因素,以及在各种临床条件下开发和测试新的诊断工具。